Literature DB >> 17565473

[Malignant hyperthermia. The ugly].

H Rüffert1, M Wehner, C Deutrich, D Olthoff.   

Abstract

The term "malignant hyperthermia" (MH), regarded as the typical anaesthetic disease, refers to a clinical syndrome of varying intensity (from abortive courses to fulminant crises) and develops only under exposure of certain triggering substances or mechanisms. MH is caused by a defect in the ryanodine receptor subtype 1, which can often be proved genetically. Furthermore, it may also be generated by other mechanisms which disturb the membranous integrity of skeletal muscle cells (e.g. some myotonias, muscular dystrophies, malformation syndromes). Hyperthermia is only one of a number of life-threatening symptoms that may occur during a fulminant crisis, which ultimately results from an excessive release of calcium into the cytoplasm of muscle cells. Due to a current good knowledge about classical triggers, symptoms and therapeutic interventions, a clinical MH presentation may successfully be treated in the perioperative period. However, it appears to be likely that there are unreported cases outside hospitals since atypical courses or alternative MH triggers (e.g. alcohol, drugs, physical stress) may impair the correct diagnosis. In contrast severe hyperthermia can also arise from other drug-induced diseases, e.g. the neuroleptic malignant syndrome or the serotonin syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565473     DOI: 10.1007/s00101-007-1218-5

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  25 in total

1.  Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia.

Authors:  S L Stewart; K Hogan; H Rosenberg; J E Fletcher
Journal:  Clin Genet       Date:  2001-03       Impact factor: 4.438

2.  Genotype-phenotype comparison of the Swiss malignant hyperthermia population.

Authors:  T Girard; A Urwyler; K Censier; C R Mueller; F Zorzato; S Treves
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

Review 3.  Heat stroke: implications for critical care and anaesthesia.

Authors:  H Grogan; P M Hopkins
Journal:  Br J Anaesth       Date:  2002-05       Impact factor: 9.166

4.  Prediction of malignant hyperthermia susceptibility by clinical signs.

Authors:  M G Larach; H Rosenberg; D R Larach; A M Broennle
Journal:  Anesthesiology       Date:  1987-04       Impact factor: 7.892

5.  Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.

Authors:  J Tong; H Oyamada; N Demaurex; S Grinstein; T V McCarthy; D H MacLennan
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

6.  Fatal malignant hyperthermia associated with recreational cocaine and ethanol abuse.

Authors:  F Loghmanee; M Tobak
Journal:  Am J Forensic Med Pathol       Date:  1986-09       Impact factor: 0.921

7.  Molecular genetic testing for malignant hyperthermia susceptibility.

Authors:  Thierry Girard; Susan Treves; Evgueni Voronkov; Martin Siegemund; Albert Urwyler
Journal:  Anesthesiology       Date:  2004-05       Impact factor: 7.892

8.  Refined genetic localization for central core disease.

Authors:  J C Mulley; H M Kozman; H A Phillips; A K Gedeon; J A McCure; D E Iles; R G Gregg; K Hogan; F J Couch; D H MacLennan
Journal:  Am J Hum Genet       Date:  1993-02       Impact factor: 11.025

Review 9.  The genetics of malignant hyperthermia.

Authors:  S P Ball; K J Johnson
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

10.  Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.

Authors:  M Wehner; H Rueffert; F Koenig; D Olthoff
Journal:  Genet Test       Date:  2003
View more
  2 in total

Review 1.  [Malignant hyperthermia].

Authors:  T Metterlein; F Schuster; B M Graf; M Anetseder
Journal:  Anaesthesist       Date:  2014-12       Impact factor: 1.041

2.  [Telephone enquiries on the topic of malignant hyperthermia: Evaluation of the content and subsequent diagnostic results at the MH Center Leipzig].

Authors:  B Petersen; T Busch; C-D Meinecke; B Börge; K Kluba; U X Kaisers; H Rüffert
Journal:  Anaesthesist       Date:  2015-10-19       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.